New therapy enters trials

INO-8875, an Adenosine 1 agonist in Phase I testing for the treatment of glaucoma, has begun patient enrolment.

Related Content:

ArticlesGlaucoma

Differences in pupil sizes distinguish between active and resolved COVID-19 cases

Consuming dried goji berries may protect against AMD

Foundation Fighting Blindness promotes Jason Menzo to president, COO